Kodiak Sciences Inc.(KOD)

Biotechnology · Palo Alto, CA

$94.63+0.82 (+0.87%)

Delayed quote: Oct 6, 2026, 3:00 PM EDT

EBITDA Yield: N/A

Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.

The EBITDA yield is N/A as of 2026-10-06T19:02:17.765Z.

Stored calculation inputs

Calculation as of: 2026-10-06T19:02:17.765Z.

Quote observation: 2026-10-06T19:00:10.000Z. Amounts in USD. The price header may show a later quote.

TTM operating EBITDA · period ending 2026-06-30: -222,914,000
Quote market capitalization: 5,921,793,992
Total debt · period ending 2026-06-30: 95,701,000
Cash · period ending 2026-06-30: 125,903,000

FMP input reference: 4147f1633fe526555426f89ecb5945f37dfc8ef4561f7e6db8f1148c00751c21

EV/EBITDA|Earnings Yield|OCF Yield|FCF Yield|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

KOD EBITDA Yield Metrics

EBITDA YIELD

N/A

KOD Competitors' EBITDA Yield

KOD

Kodiak Sciences Inc.

Current

Market Cap

$5.92B

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

IOVA

Iovance Biotherapeutics, Inc.

vs KOD

Market Cap

$5.91B

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

GRAL

GRAIL Inc.

vs KOD

Market Cap

$5.90B

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

KNSA

Kiniksa Pharmaceuticals International, plc

vs KOD

Market Cap

$5.87B

EBITDA Yield

1.79%

TTM Avg

1.65%

3Y Avg

1.60%

5Y Avg

1.99%

LGND

Ligand Pharmaceuticals Incorporated

vs KOD

Market Cap

$5.98B

EBITDA Yield

2.21%

TTM Avg

1.62%

3Y Avg

2.24%

5Y Avg

4.65%

CGON

CG Oncology Inc.

vs KOD

Market Cap

$5.64B

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

RYTM

Rhythm Pharmaceuticals, Inc.

vs KOD

Market Cap

$6.23B

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

RDNT

RadNet, Inc.

vs KOD

Market Cap

$5.52B

EBITDA Yield

4.61%

TTM Avg

4.21%

3Y Avg

4.87%

5Y Avg

6.47%

MMED

MiniMed Group, Inc. Common Stock

vs KOD

Market Cap

$5.48B

EBITDA Yield

3.28%

TTM Avg

3.04%

3Y Avg

3.04%

5Y Avg

3.04%

PTCT

PTC Therapeutics, Inc.

vs KOD

Market Cap

$5.34B

EBITDA Yield

3.44%

TTM Avg

10.75%

3Y Avg

10.29%

5Y Avg

10.29%

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
Kodiak Sciences Inc. (KOD)	$5.92B	N/A	N/A	N/A	N/A
Iovance Biotherapeutics, Inc. (IOVA)vs ›	$5.91B	N/A	N/A	N/A	N/A
GRAIL Inc. (GRAL)vs ›	$5.90B	N/A	N/A	N/A	N/A
Kiniksa Pharmaceuticals International, plc (KNSA)vs ›	$5.87B	1.79%	1.65%	1.60%	1.99%
Ligand Pharmaceuticals Incorporated (LGND)vs ›	$5.98B	2.21%	1.62%	2.24%	4.65%
CG Oncology Inc. (CGON)vs ›	$5.64B	N/A	N/A	N/A	N/A
Rhythm Pharmaceuticals, Inc. (RYTM)vs ›	$6.23B	N/A	N/A	N/A	N/A
RadNet, Inc. (RDNT)vs ›	$5.52B	4.61%	4.21%	4.87%	6.47%
MiniMed Group, Inc. Common Stock (MMED)vs ›	$5.48B	3.28%	3.04%	3.04%	3.04%
PTC Therapeutics, Inc. (PTCT)vs ›	$5.34B	3.44%	10.75%	10.29%	10.29%

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

About Kodiak Sciences Inc.

Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.

Palo Alto, CA

141 employees

kodiak.com

Healthcare / Biotechnology